Skip to main content
. Author manuscript; available in PMC: 2019 Sep 28.
Published in final edited form as: Cancer Lett. 2018 Jun 15;432:169–179. doi: 10.1016/j.canlet.2018.06.006

Figure 4.

Figure 4

Orai1 expression and translocation were not affected by RP4010. (A) Western blot of STIM1 and Orai1 was conducted in KYSE-150 cells with 10 µM RP4010 treatment for 10 min, 2 hours and 4 hours. (B) Confocal images of STIM1-mOrange and Orai1-GFP. KYSE-150 cells were treated with TG (10 µM) first to deplete ER Ca2+ stores and to activate SOCE. STIM1 and Orai1 could co-localize in control or RP4010 (10 µM) treated cells, but not cells treated with ML-9 (100 µM), a known SOCE inhibitor disrupting translocation of Orai1. Scale bar 10 µm. (C) SOCE in control and RP4010 (10 µM) treated KYSE-150 cells expressing Orai1 V102C, a constitutively active mutant. (D) Statistic of SOCE in cells expressing Orai1V102C. Mean ± SD. ***p ≤ 0.001.